NASDAQ:ICAD - iCAD Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.72 +0.09 (+1.60 %) (As of 05/21/2019 01:40 AM ET)Previous Close$5.63Today's Range$5.51 - $5.7552-Week Range$2.42 - $6.32Volume66,406 shsAverage Volume148,782 shsMarket Capitalization$99.33 millionP/E RatioN/ADividend YieldN/ABeta1.34 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, such as advanced image analysis and workflow solutions in breast imaging, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer's network that receives patient studies from the imaging modality, performs CAD and density assessment analysis, and sends the CAD results to picture archiving and communication system and/or review workstations. In addition, the company's digital mammography CAD products comprise magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves hospitals, ambulatory care centers and free standing radiation oncology facilities, and other office-based uses through sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. iCAD, Inc. has a strategic partnership agreement with Invivo Corp. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire. Receive ICAD News and Ratings via Email Sign-up to receive the latest news and ratings for ICAD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorComputer and Technology Current SymbolNASDAQ:ICAD Previous Symbol CUSIPN/A CIK749660 Webwww.icadmed.com Phone603-882-5200Debt Debt-to-Equity Ratio2.90 Current Ratio1.47 Quick Ratio1.48Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$25.62 million Price / Sales3.88 Cash FlowN/A Price / Cash FlowN/A Book Value$0.26 per share Price / Book22.00Profitability EPS (Most Recent Fiscal Year)($0.38) Net Income$-9,020,000.00 Net Margins-36.24% Return on Equity-54.45% Return on Assets-14.58%Miscellaneous Employees95 Outstanding Shares17,366,000Market Cap$99.33 million Next Earnings Date8/13/2019 (Estimated) OptionableOptionable iCAD (NASDAQ:ICAD) Frequently Asked Questions What is iCAD's stock symbol? iCAD trades on the NASDAQ under the ticker symbol "ICAD." How were iCAD's earnings last quarter? iCAD Inc (NASDAQ:ICAD) announced its quarterly earnings data on Tuesday, May, 7th. The technology company reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.15) by $0.08. The technology company earned $6.77 million during the quarter, compared to analyst estimates of $6.10 million. iCAD had a negative return on equity of 54.45% and a negative net margin of 36.24%. View iCAD's Earnings History. When is iCAD's next earnings date? iCAD is scheduled to release their next quarterly earnings announcement on Tuesday, August 13th 2019. View Earnings Estimates for iCAD. Has iCAD been receiving favorable news coverage? Press coverage about ICAD stock has trended somewhat negative this week, InfoTrie reports. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. iCAD earned a news sentiment score of -1.6 on InfoTrie's scale. They also assigned media coverage about the technology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. Who are some of iCAD's key competitors? Some companies that are related to iCAD include GenMark Diagnostics (GNMK), MiMedx Group (MDXG), Accuray (ARAY), Inovio Pharmaceuticals (INO), Utah Medical Products (UTMD), Westaim (WEDXF), Vapotherm (VAPO), Neuronetics (STIM), SeaSpine (SPNE), Pulse Biosciences (PLSE), Iradimed (IRMD), Cytosorbents (CTSO), Apyx Medical (APYX), Alphatec (ATEC) and Liquidia Technologies (LQDA). What other stocks do shareholders of iCAD own? Based on aggregate information from My MarketBeat watchlists, some companies that other iCAD investors own include Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), Sensus Healthcare (SRTS), Palatin Technologies (PTN), Biocept (BIOC), CymaBay Therapeutics (CBAY), Catalyst Biosciences (CBIO), Avid Bioservices (CDMO), Genocea Biosciences (GNCA) and GenMark Diagnostics (GNMK). Who are iCAD's key executives? iCAD's management team includes the folowing people: Ms. Stacey M. Stevens, Pres (Age 51)Mr. Michael S. Klein, Exec. Chairman & CEO (Age 65)Mr. R. Scott Areglado, VP, Corp. Controller & Interim CFO (Age 55)Mr. Jonathan Go, Chief Technology Officer (Age 56)Ms. Annette L. Heroux, VP of Admin. (Age 62) Who are iCAD's major shareholders? iCAD's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.42%), Schonfeld Strategic Advisors LLC (1.58%), EAM Global Investors LLC (1.10%), Dimensional Fund Advisors LP (0.38%), Columbia Pacific Advisors LLC (0.37%) and Acadian Asset Management LLC (0.24%). View Institutional Ownership Trends for iCAD. Which institutional investors are selling iCAD stock? ICAD stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Jacobs Levy Equity Management Inc., Dimensional Fund Advisors LP, Bank of Montreal Can, BlackRock Inc., Sprott Inc. and Taylor Cottrill Erickson & Associates Inc.. View Insider Buying and Selling for iCAD. Which institutional investors are buying iCAD stock? ICAD stock was bought by a variety of institutional investors in the last quarter, including Schonfeld Strategic Advisors LLC, EAM Global Investors LLC, Columbia Pacific Advisors LLC, Acadian Asset Management LLC, Spark Investment Management LLC, Northern Trust Corp, Charles Schwab Investment Management Inc. and Advisor Group Inc.. View Insider Buying and Selling for iCAD. How do I buy shares of iCAD? Shares of ICAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is iCAD's stock price today? One share of ICAD stock can currently be purchased for approximately $5.72. How big of a company is iCAD? iCAD has a market capitalization of $99.33 million and generates $25.62 million in revenue each year. The technology company earns $-9,020,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis. iCAD employs 95 workers across the globe. What is iCAD's official website? The official website for iCAD is http://www.icadmed.com. How can I contact iCAD? iCAD's mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The technology company can be reached via phone at 603-882-5200 or via email at [email protected] MarketBeat Community Rating for iCAD (NASDAQ ICAD)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 100 (Vote Outperform)Underperform Votes: 111 (Vote Underperform)Total Votes: 211MarketBeat's community ratings are surveys of what our community members think about iCAD and other stocks. Vote "Outperform" if you believe ICAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICAD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/21/2019 by MarketBeat.com StaffFeatured Article: Do Tariffs Work? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.